Literature DB >> 34196064

PET/CT-Detected myofibroblastoma of the breast with bizarre cells: A potential diagnostic pitfall of malignancy.

Giuseppe Angelico1, Giuseppe Broggi2, Saveria Spadola1, Antonino Mulè1, Gaetano Magro2.   

Abstract

Myofibroblastoma (MFB) is a rare benign mesenchymal tumor usually occurring in the breast parenchyma. This tumor can present as a palpable nodule or can be incidentally detected as a nonpalpable mass on routine screening mammogram. We first report a rare case of histologically proven MFB of the breast revealed by fluoro-deoxyglucose uptake on PET-CT examination in a patient with a lung nodule. Tumor exhibited an unusual morphology, being predominantly composed of polygonal, epithelioid, and deciduoid-like cells set in a myxoid stroma. The most striking feature was the multifocal presence of atypical/bizarre, mono/bi-nucleated cells that, in addition to diffuse myxoid stromal changes, were a concern of malignancy, especially on core biopsy. The final diagnosis of MFB was achieved on surgically resected specimen and, similarly to other benign soft tissue tumors (especially leiomyoma and schwannoma/neurofibroma), the term "bizarre cell MFB of the breast" is proposed to emphasize the degenerative/reactive nature of the atypia.
© 2021 The Authors. The Breast Journal published by Wiley Periodicals LLC.

Entities:  

Keywords:  PET/CT; atypical/bizarre cells; breast; myofibroblastoma; soft tissue tumor

Year:  2021        PMID: 34196064     DOI: 10.1111/tbj.14269

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  2 in total

1.  Application of PET/CT in Preoperative Evaluation and Diagnosis of Gastric Cancer.

Authors:  Xin Zhou; Yongpeng Zhang; Xipeng Zhao; Lin Zhou; Xia Jia; Libo Pan
Journal:  Comput Math Methods Med       Date:  2022-04-04       Impact factor: 2.238

2.  Myofibrosarcoma infiltrating pulmonary arteries diagnosed on 18F-FDG PET/CT.

Authors:  Weijun Wei; Yumei Chen; Xiaojing Zhao; Jianjun Liu; Min Cao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.